EP 3829572 A1 20210609 - USE OF NEUROKININ-1 ANTAGONISTS TO TREAT CHRONIC PRURITUS
Title (en)
USE OF NEUROKININ-1 ANTAGONISTS TO TREAT CHRONIC PRURITUS
Title (de)
VERWENDUNG VON NEUROKININ-1-ANTAGONISTEN ZUR BEHANDLUNG VON CHRONISCHEM PRURITUS
Title (fr)
UTILISATION D'ANTAGONISTES DE NEUROKININ-1 À DES FINS DE TRAITEMENT DU PRURIT CHRONIQUE
Publication
Application
Priority
- US 201862711123 P 20180727
- US 201862779285 P 20181213
- US 201962821126 P 20190320
- US 2019043710 W 20190726
Abstract (en)
[origin: WO2020023898A1] The disclosure relates to the use of neurokinin-1 (NK-1) antagonists, such as serlopitant, in treating chronic pruritus with a duration of at least about 6 months or 1 year. In some embodiments, the chronic pruritus is characterized by sensitization or hypersensitization of central neuron or/and peripheral neurons. In further embodiments, the chrome pruritus is characterized by spontaneously occurring itch, alloknesis or hyperknesis, or any combination or all thereof. The chronic pruritus can be associated with any medical conditions or can have an unknown cause (idiopathic). One or more additional antipruritic agents can optionally be used in combination with an NK-1 antagonist to treat chronic pruritus.
IPC 8 full level
A61K 31/403 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 31/4035 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01)
CPC (source: EP)
A61K 9/20 (2013.01); A61K 31/4035 (2013.01); A61K 45/06 (2013.01); A61P 17/04 (2017.12)
Citation (search report)
See references of WO 2020023898A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
DOCDB simple family (application)
US 2019043710 W 20190726; EP 19840295 A 20190726